- Home
- AMP vs ALNY Comparison
AMP vs ALNY Comparison
Compare AMP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMP
- ALNY
- Stock Information
- Founded
- AMP 1894
- ALNY 2002
- Country
- AMP United States
- ALNY United States
- Employees
- AMP N/A
- ALNY N/A
- Industry
- AMP Investment Managers
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- AMP Finance
- ALNY Health Care
- Exchange
- AMP Nasdaq
- ALNY Nasdaq
- Market Cap
- AMP 48.6B
- ALNY 39.6B
- IPO Year
- AMP 2005
- ALNY 2004
- Fundamental
- Price
- AMP $510.32
- ALNY $309.70
- Analyst Decision
- AMP Hold
- ALNY Strong Buy
- Analyst Count
- AMP 6
- ALNY 25
- Target Price
- AMP $514.60
- ALNY $324.96
- AVG Volume (30 Days)
- AMP 442.5K
- ALNY 849.2K
- Earning Date
- AMP 07-23-2025
- ALNY 07-31-2025
- Dividend Yield
- AMP 1.26%
- ALNY N/A
- EPS Growth
- AMP 0.13
- ALNY N/A
- EPS
- AMP 29.43
- ALNY N/A
- Revenue
- AMP $18,082,000,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- AMP N/A
- ALNY $30.77
- Revenue Next Year
- AMP $4.93
- ALNY $30.51
- P/E Ratio
- AMP $17.27
- ALNY N/A
- Revenue Growth
- AMP 9.09
- ALNY 17.21
- 52 Week Low
- AMP $385.74
- ALNY $153.23
- 52 Week High
- AMP $582.05
- ALNY $317.54
- Technical
- Relative Strength Index (RSI)
- AMP 52.18
- ALNY 63.60
- Support Level
- AMP $504.20
- ALNY $295.82
- Resistance Level
- AMP $514.04
- ALNY $317.54
- Average True Range (ATR)
- AMP 8.55
- ALNY 7.74
- MACD
- AMP -1.75
- ALNY -0.67
- Stochastic Oscillator
- AMP 47.74
- ALNY 63.90
About AMP Ameriprise Financial Inc.
Ameriprise Financial is a major player in the US market for asset and wealth management, with around $1.5 trillion in total assets under management and administration at the end of 2024. With about 10,500 advisors, Ameriprise has one of the largest branded advisor networks in the industry. About 80% of the company's revenue comes from its asset and wealth management segments. Ameriprise has reduced its exposure to insurance with the sale of its auto and home insurance business in 2019 and discontinuing the sale of proprietary fixed annuities in 2020.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.